
Dockets Management Brain The Food and Drug Admir Department of Health &H 12420 Parklawn Dr. Rockville, MD 20857	nistration ruman Services, Rm. 1-23		Date:
Re: 99P-1340/CP 1 — Petit	ion to Have Eternity eau de par	fum declared "Misbrand" 0 8 4 6 199 S	🕶 🚗 - G. Aller St. S.
Dear Sir or Madam:	The second of th	and the second s	Committee of the Commit
 Eternity eau de parfum der that the FDA give it careful 21CFR Sec. 740.10. Regular Each ingredient used stantiated for safety posubstantiated prior to the principal display with the warning. "Warning. 	Il attention with regard to you tion 21CFR Sec. 740.10 states: in a cosmetic product and each rior to marketing. Any such is marketing is misbranded unlepanel: Ity of this product has not been	r regulations 21CFR Second finished cosmetic pro- ngredient or product whees it contains the following determined."	duct shall be adequately sub- nose safety is not adequately ving conspicuous statement on
tiated. There is no warning	g label on its packaging.		safety have not been substan-
We all have a right to ke we can protect ourselves a are not aware that most fro products are safe to use in	now the status of safety testing and our families from toxic che agrance materials have only li any setting and are surprised	emicals that may cause I mited safety testing. The when people complain	**
people, including: people es. Children are particular parents, caregivers and ter	ly violagrable to toxic chemica	vities, crironic latigue, and its found in products pu fragrance products I ca	IN Other Strationing miness
B asthma	double vision	incoherence -	a nausea
□ anaphylaxis	a ear pain	incontinence ,	nose bleeds
anxiety, restlessness	□ eczema	irritability	□ rashes
- breathing difficulty	eyes, watery or dry	joint aches	seizures
☐ bronchitis	13 fatigue	□ laryngitis	short-term mem. loss
can't concentrate	S flushing	lethargy	ausitis
coughing	headaches	☐ lymph nodes swel	sneezing
depression	heart beat irregularity	mood swings	sores, skin/mouth
disorientation	D hives		kness Swallowing difficulty
dizziness	□ hypertension \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	nasal congestion	S tinnitus
other: 15n+ +1	113 énorgh		And the second s
Please act on behalf of t	a and chemical sensitivities. !	ings. These toxic chemic	als act as powerful builties
your name	(S. A. D. (260 NM 87	Stock The state of
P.O. BOX 1588	son jan me		- V
address; city/st/zip 999-1340 Newsletters and everyone	who feels people have a right to know	, please copy, share, tell your fr	iends and WRITE the FDAtoday!

first, fold down





Attn: 99P-1340/CP 1

Dockets Management Branch
The Food and Drug Administration
Department of Health &Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

Labella de la la



second, fold up

tape shut